Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Natco Will File India, Nepal Compulsory License Applications For Generic Versions Of Pfizer's Cancer Drug Celzentry

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Natco Pharma told PharmAsia News it plans to file a compulsory license application to sell a generic version of Pfizer's HIV/AIDS drug Celzentry (maraviroc) in Nepal and India, the third such application by the firm, which has cited the high cost of the drugs to the patent office in India as the backbone of its cases

You may also be interested in...



Senior Judges At Indian Legal Symposium Call For Review Of Patent Act

BANGALORE, India - Two senior judges have called for legal challenges and legislative changes to India's patent act, saying the law last amended in 2005 to comply with World Trade Organization guidelines favors multinational drug firms

Senior Judges At Indian Legal Symposium Call For Review Of Patent Act

BANGALORE, India - Two senior judges have called for legal challenges and legislative changes to India's patent act, saying the law last amended in 2005 to comply with World Trade Organization guidelines favors multinational drug firms

PharmAsia News India Pharma Roundup: Natco, Strides Arcolab, Glenmark, Ranbaxy/Pfizer, Merck

NEW DELHI - Natco Pharmaceuticals said it is mulling its options after a court decision March 19 to allow Cipla to continue to make and sell Roche's lung cancer drug Tarceva (erlotinib) in India (PharmAsia News, March 20, 2008)

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel